However, a meta-analysis of the AMPLITUDE-O and HARMONY Outcomes trials demonstrated that GLP-1 RA therapy reduced the risk of atherosclerotic cardiovascular events and hospitalization due to heart failure, independently of baseline SGLT2 inhibitor use, suggesting an additional risk-reducing effect of the combination therapy [126]. The gene discussed is SLC5A2; the disease is heart failure.